StockData
aTYR PHARMA INC logo

aTYR PHARMA INC (ATYR) company profile

ATYRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$4.99−0.25 (-4.77%)

Close on Nov 17, 2026Market cap $489.46MP/E –Yield –

About aTYR PHARMA

Biological Products, (No Diagnostic Substances), SIC 2836

aTyr Pharma, Inc. is a clinical-stage biotechnology company that utilizes evolutionary intelligence to translate tRNA synthetase biology into therapies for fibrosis and inflammation. Its discovery platform identifies signaling pathways driven by domains derived from all twenty tRNA synthetases to unlock potential therapeutic intervention points. The company's lead therapeutic candidate is efzofitimod, a biologic immunomodulator designed to treat interstitial lung diseases such as pulmonary sarcoidosis and systemic sclerosis-associated interstitial lung disease. Additionally, the company develops pipeline candidates including ATYR0101 for fibrotic diseases and ATYR0750 for inflammatory and fibrotic conditions.

The company operates in the United States and has an international collaboration with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod in Japan. It also maintains a subsidiary, Pangu BioPharma Limited, in Hong Kong. aTyr Pharma is headquartered in San Diego, California.

Summary of the business section of aTYR PHARMA's latest annual report, written by StockData.

Company profile

Company

Legal name
aTYR PHARMA INC
Founded
2005
Headquarters
San Diego, CA
Address
10240 Sorrento Valley Road, Suite 300 92121
Phone
(858) 731-8389
Employees
58, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, San Diego, California

Stock & identifiers

Ticker
ATYR
Former tickers
LIFE until Jul 22, 2024
Exchange
Nasdaq
IPO date
May 7, 2015
Shares outstanding
98M, Jul 31, 2026
Public float
$463.82M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-14 reverse, Jul 1, 2019
SEC CIK
1339970
CUSIP
002120202
ISIN
US0021202025
FIGI
BBG001J2P692
Share class FIGI
BBG001V0GF01
LEI
529900ENQUXMC5EBKO36
EIN
20-3435077

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Sanjay ShuklaPresident and CEO, Director153,553
Brandon YarasChief Financial Officer–
Jill Marie BroadfootChief Financial Officer37,296
Nancy DenyesGeneral Counsel33,124
Paul SchimmelDirector2,201,056
Jane A. GrossDirector9,750
Sara ZaknoenDirector6,000
Svetlana LucasDirector6,000
Timothy CoughlinDirector56,000
Eric BenevichDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$3.46M$575.97K$1.30M$36–
FY2024$1.48M$3.14M$737.73K$165–
FY2023$1.30M$596.67K$664.56K$64–
FY2022$2.41M$480.85K$885.51K$29–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
May 7, 2015
Offer price
$14.00
Securities offered
5,360,000
Gross proceeds
$75.04M
Exchange
Nasdaq
Lock-up ends (est.)
Nov 3, 2015

“The initial public offering price of our common stock is $14.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 58 employees, 56 of which were full-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?